- Maintaining a Neutral rating while raising the price target to $40, Goldman's Terence Flynn says yesterday's trial results should support U.S. approval in Q2 of 2015. He's raising the probability of approval to 100% from 30% and raising his estimate of peak market share to 50% from 30%, but not changing pricing or compliance assumptions. "We expect complete data to be presented at the ATS conference in May, where we also hope to gain insight on the competitive landscape with the potential presentation of Ph3 data from Boehringer Ingelheim's BIBF-1120."
- Not convinced sales will be as large as the market is currently pricing in, Jefferies' Eun Yang maintains his Underperform rating while lifting the price target to $20. "Our new $20 PT is based on U.S./EU peak sales estimates of $650M/$300M, not a conservative assumption in our view."
- Its work here done, Leerink Swan removes its Buy rating on the stock.
- ITMN is giving back just a bit of yesterday's moonshot, -12.7% to $32.99.